INTRODUCTION
Viral hepatitis is an inflammation of the liver that may progress spontaneously to healing or lead to cirrhosis or hepatocellular carcinoma (HCC). Viral hepatitis cau sed 1.34 million deaths in 2015, a figure comparable to deaths from tuberculosis (TB) and human immuno deficiency virus (HIV). However, mortality attributable to TB and HIV is decreasing, while that due to hepatitis is constantly increasing [1] . There are five types of hepa titis viruses designated by the letters A, B, C, D and E. The most common forms of the disease are hepatitis A, B and C. Another human lymphotropic virus be longing to the Flaviviridae family and closely related to hepatitis C virus (HCV) was identified as hepatitis G virus (HGV) or GB virus C (GBVC). However, several studies have shown that GBVC/HGV infection is not clearly associated with any disease and may play a role in modulating HIV disease [2, 3] . In a study conducted in Burkina Faso, a prevalence of 7.4% of HGV was reported in blood donors [4] . Viral hepatitis usually occurs as a result of parenteral contact with infected body fluids: Blood transfusions or contaminated blood products. Hepatitis B virus (HBV) is ubiquitous, but the pre valence of infection varies across different regions of the world. According to the World Health Organization, about two billion people have been in contact with HBV worldwide, with more than 240 million cases of chronic infections [5] . About 80 to 120 million cases of chronic HBV infection occur in subSaharan Africa [6, 7] . According to the carriage of hepatitis B surface antigen (HBsAg), there are zones of low endemicity (< 2%) such as Western Europe or North America; areas of average prevalence (2%7%) such as North Africa or Eastern Europe and finally high endemic areas (> 8%) such as West Africa or Southeast Asia [8] . Indeed, hepatitis B is highly endemic in West Africa, with the highest prevalence in the world (> 8%). In subSaharan Africa, about 47% of HCC have been attributed to HBV [9] . Despite the availability of a vaccine, HBV remains a major public health problem, with approximately 686 thousand deaths per year worldwide due to the consequences (cirrhosis and HCC) of this infection [5] . More than 71 million people worldwide are chroni cally infected with HCV and may develop liver cirrhosis and/or HCC [10] . There is currently no effective vaccine against HCV; and about 399000 people die each year from hepatitis C, mainly cirrhosis and HCC. In North and West Africa, the prevalence of HCV infection ranges from 0.5% to 1.0% [10] . Hepatitis delta virus (HDV) is a small defective ribonucleic acid (RNA) virus that depends on HBV for the assembly of new virions and proliferation of infection to hepatocytes. HDV infection can be therefore prevented through vaccination or any strategy to eliminate HBV infection. Approximately 15 to 20 million people worldwide are coinfected with these two viruses, with a high risk of severe liver disease [11] . In a study of pregnant women in Benin, the prevalen ce of HDV was 11.4% in 15.5% of HBsAgpositive individuals [12] . There are several genotypes of hepatitis viru ses with different clinical implications and distinct geographic distributions. HBV is classified into 10 genotypes (AJ) and about 40 subgenotypes with a correlation between genotypes and their modes of transmission [13] . In fact, HBV genotype A is found in North America, Europe, SouthEast Africa and India; genotypes B and C in Asia and Oceania while genotype D is the most common in North America, North Africa, Europe, the MiddleEast and Oceania. HBV genotype E is hyperendemic in West Africa; genotype F is found in
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HBV infection
HBV belongs to the Hepadnaviridae family and the Orthohepadnavirus genus [23] . It is a doublestranded circular DNA enveloped virus of small circumference (1.6 million Dalton) associated with a DNAdependent DNA polymerase that acts as a reverse transcriptase during replication. HBV is highly contagious, 100 times more contagious than HIV and can remain stable at 25 ℃ for seven days in dried blood. Sexual, parenteral (through the blood), mothertochild or even close intrafamily nonsexual contact over a long period of time are the different modes of infection. The most common modes of spread of hepatitis B in endemic areas are mothertochild transmission and exposure to infected blood. The appearance of a chronic infection is very common for infants infected by their mother before the age of 5 years.
Markers, such as the HBsAg, the HBs antibody (antiHBs), the core antigen (HBcAg), the HBe antigen (HBeAg) and the HBe antibody (antiHBe) make it possible to monitor the evolution of this virus. Despi te the small size of the genome and the constraints imposed by its organization, HBV is highly variable.
HBV strains are divided into several genotypes. These genotypes are defined by a divergence of at least 8.0% of the whole genome nucleotide sequence and at least 4.1% in the S gene [24] . The main genotypes were divided into subgenotypes based on the divergence between 4.1% and 8.0% of their complete nucleotide sequence [25] . In the last decade, phylogenetic studies of sequences of different viral genomes have tentati vely classified HBV into 10 genotypes (AJ) [26] . Geno types and subgenotypes have a distinct geographic distribution [27] . Genotype A is the only predominant genotype in East Africa, where the prevalence of other genotypes is less than 5% [24, 28] . The subgenotype A1 is predominant in Africa, while subgenotypes A3A6 are found in Central and West Africa [29] . Subgenotype D1 is highly prevalent in East Africa [30] ; D7 has been isolated in Tunisia [31] ; and D8 has been characterized in Niger [32] . West Africa is the main focus of genotype E. Vaccination is the safest way to prevent HBV infection [33] . Major advances in the treatment of chronic HBV have been made with the development of nucleoside reverse transcriptase inhibitors with anti HBV activity, such as Lnucleosides (lamivudine 3TC) or alkylphosphates (tenofovir disoproxil fumarate) [34] .
HCV infection
HCV belongs to the family Flaviviridae and the genus hepacivirus [35] . HCV mainly infects hepatocytes but may also be present in blood mononuclear cells and dend ritic cells [36] . HCV is a small singlestranded RNA virus of positive polarity, enveloped 5565 nm in diameter. South America; and genotypes G and H are in Central and South America [13] . HCV has a high genetic diversity with a predominance of genotype 1 and 3 worldwide. The endemic strains of genotypes 1 and 2 are mainly found in West Africa, genotype 3 in Asia, genotypes 4 in Central Africa and the Middle East, while genotypes 5 and 6 are predominant in South Africa and South East Asia, respectively [14] . HCV genotype 2 is the most common genotype in West African countries, followed by genotype 1 and genotype 3 [15] . HDV genotype Ⅰ is more common in Europe and North America, genotype Ⅱ is predominant in the Far East and Japan while genotype Ⅲ is predominant in the Amazonian area and northern South America [16] . The severity of hepatic pathology and the response to treatment depend on the virus genotype in the infected host. For example, HBV genotype A infection tends to chronicity, whereas genotype D has a high frequency of mutation influencing response to treatment. Liver cirrhosis and progression to HCC are strongly associated with HBV genotypes C and D compared to other genotypes [17, 18] . Furthermore, superinfection of chronic HBV patients by HDV leads to increased liver damage and more rapid progression of cirrhosis in 90% of cases [16] . HDV genotype Ⅲ is thought to be associated with severe forms of liver disease, while a more moderate clinical evolution and a wide variety of clinical conditions are observed with genotypes Ⅱ and Ⅰ, respectively. The response to interferon treatments is more effective against HBV genotypes A and B compared to genotypes C, D and Ⅰ. HBV genotype E seems to have the worst response to treatment [18] . Rapid progression of hepatic disease and HCC has also been associated with HBV genotype A1 [13] . HCV subtype 1b is associated with a high risk of developing HCC compared to other genotypes [19] . Early generations of vaccines protected against subtype 1b, while genotype 3, which accounts for 30.1% of HCV global infections, is less likely to respond to first and second generation directacting antivirals currently used for HCV treatment [14, 20] . Determination of the viral genotype is an essential element of the pretherapeutic assessment, because it is one of the predictors of the response to treatment and determines the choice of molecules used with the new antiHCV treatments. It has also been shown that HBV genotypes differ according to disease co urse, mutation development and response to anti viral therapy [21] . Indeed, genotype determination is important to identify patients who are at increased risk of disease progression and to optimize treatment [22] . Here, we review various publications on the genotypes of hepatitis viruses in West African countries [West African Economic and Monetary Union (WAEMU) coun tries, Ghana and Nigeria] in order to map the geno types distribution and discuss the infections associated with the different viruses identified.
Parenteral route is the major mode of transmission of HCV. Transfusion and intravenous drug addiction are also routes of transmission. To this day, the main cause of HCV transmission in developed countries is drug abuse [37] . The HCV genome shows a high rate of mutations with considerable genetic heterogeneity of the virus in infected people worldwide. Phylogenetic approaches made it possible to classify HCV into 11 major genotypes (designated by the Arabic numerals from 1 to 11), with many subtypes (indicated by lower case letters a, b, c, etc.) [38] . Subgenotypes 1a, 1b, 2a, 2b and 3a are widely distributed worldwide [39] , while 5a and 6a are com mon in South Africa and Southeast Asia [40, 41] . Genotype 4 is predominant in Central Africa [42, 43] and in North Africa [44] . In Africa, divergent HCV genotype 1 and 2 strains were found endemic in the West African subregion [4547] . Recently, analysis of the epidemic his tory of HCV infections has traced modern HCV lines in West Africa to the 17 th and 20 th centuries [46] . The cu rrent standard treatment for chronic infection is the combination of pegylated interferon alpha (pegIFNα) and ribavirin (RBV) [48] . Currently, new therapeutic approaches using directacting antivirals have been developed for the treatment of chronic hepatitis C. These molecules inhibit certain stages of the viral cycle and prevent the production of viral particles by infected hepatocytes.
Others hepatitis virus infection (HDV and HGV)
HDV infection: HDV is an infectious agent that can only infect patients previously or simultaneously infected with the HBV [49] . It is a singlestranded RNA negative polarity virus, 1700 nucleotides in size, which encodes a single structural protein, the hepatitis delta antigen (HDAg), and requires HBV to replicate. HDV infection can only occur with simultaneous coinfec tion with HBV or superinfection [1] . HDV transmission is predominantly parenteral, and the sexual route is less effective than HBV. Mothertochild transmission is rare. Hepatitis D is a liver disease that can take the acute form and chronic form. There can be no hepatitis D in the absence of HBV. Coinfection with HBV or HDV superinfection results in more severe disease than HBV monoinfection [1] . HDV infection is diagnosed by high titers of immunoglobulin G (IgG) and immunoglobulin M (IgM) antiHDV and confirmed by serum detection of HDV RNA by polymerase chain reaction [1] . HDV isolates in the world are divided into at least eight phylogenetically distinct genotypes [50] . Genotype 1 is the predominant form of HDV with worldwide distribution, while genotypes 2 and 4 are present in Japan and Taiwan and are often associat ed with a milder form of disease [50] . Genotype 3 has been reported in the Amazonian region [51] . Genotypes 58 were detected in the sera of patients of African origin [52] . In addition, genotype 8 infection was also detected in the state of Maranhão in northeastern Brazil [53] . Some studies have shown that genotypes 3 and 4 can be associated with particularly severe clinical forms of hepatitis (fulminant hepatitis) [51] . HDV infection is rarely studied in West Africa despite the high prevalence of HBV. There is currently no effective antiviral therapy for hepatitis D. The prevention of hepatitis D involves vaccination against hepatitis B. pegIFNα is the only effective antiHDV drug; nucleoside analogues active against HBV have little or no effect on HDV replication [1] .
HGV infection:
The HGV, called GBVC or HGV, is a flavivirus, such as HCV, that causes spontaneously resolving acute hepatitis or fulminant hepatitis. It can cause chronic infections. HGV is a singlestranded positivestrand RNA virus [54] . Its transmission is mainly parenteral. Maternalfetal and sexual transmissions are higher than those seen with HCV. IFN is effecti ve in normalizing hypertransaminasemia in infected patients, but relapse appears to be common when treatment is discontinued.
METHODOLOGY
Research strategy and selection criteria
A systematic review of the literature was conducted to identify relevant articles reporting genotypes of hepatitis viruses in WAEMU countries including Ghana and Nigeria from 1996 to 2018. The research was con ducted in French and/or English in three databases: PubMed, Google Scholar and Science Direct. The key words used were "HBV and/or HBV and other viruses "+" the name of each of the 10 countries included in the study". A filter limiting the search for keywords in the title and/or abstract of articles was used [PubMed: (tiab); Google Scholar: Allintitle and Science Direct: TITLEABSTRKEY]. Searches with similar terms such as "hepatitis virus", "hepatitis virus", "hepatitis virus genotypes" or "hepatitis virus genotype" were also conducted.
The studies were then selected on the basis of the following criteria: (1) data published in a peerreviewed scientific journal; (2) only patients residing in one of the WAEMU countries, Ghana or Nigeria; and (3) patients from these countries infected with hepatitis viruses whose genotypes have been identified. All scientific publications (52) that reported data on genotypes of hepatitis viruses in populations from WAEMU countries, Ghana and Nigeria, between 1996 and 2018 and met the selection criteria were included in this systematic review (Figure 1 ). Eligible studies had to report the genotype of viral hepatitis in populations from included countries regardless of method used for viremia de tection. Both risk groups or general population were eligible for inclusion.
HBV and HCV viremia detection were based on DNA/RNA amplification. Genotypes detection was performed using polymerase chain reaction or direct sequencing. HCV genotype classification was considered because in many studies, HCV cases were classified at the genotype level but not at the subtype level. Journal articles, publisher correspondence, news, letters, book chapters and studies whose data were ambiguous or could not be extracted were systematically excluded. The search and selection of the relevant articles in the three databases were carried out by two independent reviewers. The inclusion of a study by both reviewers was a requirement. In case of disagreement on the eligibility of a study, the problem was solved through a discussion and/or consensus with a third reviewer.
Extractions of data and analysis
The genotyping data were extracted from the different studies carried out in Ghana, Nigeria and WAEMU countries. The data extracted from the various studies included in this review are: The first author, the year of the data publication, the study population, the type of study or data collection (prospective or retrospective), the country, the number of samples successfully gen otyped and the results of identified genotypes. In multicenter studies, only data from the cou ntries included in this minireview were considered. Prevalence was determined by making the ratio of the genotype considered to the total number of samples tested for that genotype. Confidence intervals were calculated using the R software. Phylogenetic analysis was performed with 53 HBV sequences using the neighborjoining algorithm based on the Kimura two parameter distance estimation method. Only bootstrap values of > 80% are shown (1.000 replicates). The maps were made using genotyping data from each country (source: Dr. Ouattara AK).
SEARCH RESULTS
Selection of studies
The initial search in the three databases, according to the search strategy described in the methodology, found 391 articles after elimination of reviews and duplicates. Examination of titles and abstracts led 
Characteristics of included studies
Tables 1 and 2 present the characteristics of the different studies included in this systematic review. The majority of included studies used a prospective method of sample collection. A casecontrol study, two Cas reports, two multicenter studies and four cohort studies were included in the review, while the rest were crosssectional or prospective studies. Twelve studies were performed in HIVinfected individuals compared to 11 in blood donors and seven in pregnant women, while populations and age groups were variable for the rest of the studies.
HBV genotypes
The frequency of the different genotypes was deter mined by dividing the number of samples presenting the genotype considered by the total number of successfully sequenced samples. In this systematic review, the largest number of successfully sequenced samples were recorded in Ghana (457/1620), followed by Nigeria (269/1620) and Côte d'Ivoire (251/1620). Genotyping studies of hepatitis viruses were rare in GuineaBissau and almost nonexistent in Togo. The HBV genotype E was the predominantly isolated geno type in the various studies conducted in the WAEMU countries, Ghana and Nigeria (Table 1) .
Indeed, out of a total of 1620 successfully sequ enced HBV samples, E genotypes were individually isolated in 90.6% (1468/1620, 95%CI: 0.8910.920) of HBV infection cases. In addition, its prevalence of recombination or coinfection with genotypes A and D was estimated at 0.86% (14/1620, 95%CI: 0.0050.014) in our study area. HBV genotype E is char acterized by low genetic diversity compared to other genotypes, including genotype A (Figure 2 Table 2 ). Figure 3 shows the geo graphical distribution of the different HBV genotypes in the countries included in this review.
Genotypes of other hepatitis viruses (HCV, HDV, HAV)
Of the 535 strains of HCV isolated and sequenced successfully, genotype 1 was found in the majority of cases of infections (56.4% or 298/528) against 40.0% (211/528) for genotype 2 while 3.6% (19/528) of the samples had genotypes 3 (9/19), 4 (7/19) and 5 (3/19) of HCV. HCV genotype 2 was most common in Benin, Burkina Faso, Ghana Guinea Bissau and Mali, while genotype 1 was predominant in Côte d'Ivoire, Senegal and Nigeria (Figure 4) , with a high number of sequenced samples. Genotypes 1 of other hepatitis viruses such as HDV, a satellite virus still found in coinfection with HBV, HAV, HGV, and HEV genotype 3, have been reported in some studies in Ghana and Nigeria (Table 2) .
DISCUSSION
Selection of studies
The aim of this review was to map the genotypes of the different hepatitis viruses identified in WAEMU countries, Ghana and Nigeria. The systematic review in the PubMed, Google Scholar and Sciences Direct databases included 52 studies reporting genotypes of hepatitis A, B, C, D, E and G. The availability of gene tic data varied across country due to the prevalence or clinical relevance of the virus or the difficulty of sequencing in a context of limited resources. Indeed, most of the genotyping studies (29/52) focused on HBV because of its endemicity in subSaharan Africa and its clinical implications [1] . In West Africa, chronic carriage of HBV in the general unvaccinated population is estimated to be between 10% and 18% [55] . Seve ral studies (18/52) have also provided HCV genotype data, which is the second virus of clinical interest in this West African subregion after HBV, while very little genetic data is available on HDV, a satellite of HBV. The genetic data on HAV come only from Nigeria where it is endemic [56] , while the genotypes of hepatitis E and G viruses, very scarce in WAEMU countries [57] , were reported respectively in Nigeria and Ghana.
HBV genotypes
Knowledge of hepatitis viruses genotypes is of great epidemiological and clinical interest. Indeed, genoty pes are responsible for variable clinical manifestations with differences depending on the stage of the dise ase, mutations and response to treatments [58, 59] . They are also an invaluable tool for mapping the molecular evolution and dynamics of infection transmission beca use the different genotypes have a distinct geogra phic distribution. The study of Archampong et al [59] November 27, 2018|Volume 10|Issue 11| demonstrated that the majority of HBVpositive and patients coinfected with lamivudine 3TC resistance were infected with HBV genotype E. This review con firms the endemicity of HBV genotype E, with a pre valence of 90.6% (1468/1620, 95%CI: 0.8910.920) and a predominance of serotype awy4. Indeed, some studies conducted in Ghana [60, 61] , Burkina Faso [62] and
Mali [63] exclusively reported the HBV genotype E in Diarra et al [80] 2018 Burkina Faso Occult HBV Crosssectional 21 E (17) and A3 (4) Archampong et al [59] 2017 Ghana HBV-HIV coinfected
Crosssectional 63 E (58), A (4) and D (1) Boyce et al [58] 2017 Ghana HBV-HIV coinfected Case reports 3 D/E (3)
Cella et al [63] 2017 Mali Malian refugees
Crosssectional
16
E (16) Lawson-Ananissoh et al [81] 2017 Côte d'Ivoire Chronic HBV Prospective 33 E (27), A (6) Dongdem et al [73] 2016 Ghana Chronic Hepatitis B
Crosssectional 58 E (47), A (8) and D (3) Opaleye et al [82] 2016 Nigeria HBV+ Crosssectional
17
E (17) Compaore et al [62] 2016 Burkina Faso HIV-1+ and HIV-1-
Candotti et al [83] 2016 Burkina Faso Blood donors Prospective 99 E (71) A3QS (28) Brah et al [84] 2016
Niger HBV infected Prospective 23 E (21), A3E (1) and D/E (1) Boyd et al [85] 2016
Côte d'Ivoire HBV-HIV coinfected Prospective 100 E (98) and A (2) Ampah et al [61] 2016 Ghana Randomized volunteers
Prospective 52 E (52) Traore et al [55] 2015 Mali Adults volunteers Faleye et al [86] 2015 Nigeria Pregnant women
Crosssectional 6 E (6)
Faleye et al [87] 2015 Nigeria Asymptomatic individuals
Crosssectional 13
E (13) Maylin et al [88] 2015 Senegal Chronic HBV Cohort study 87 E (65), A (22) Honge et al [76] 2014
Guinea-Bissau HIV+ Crosssectional 26 E (25) and D (1) De Paschale et al [12] 2014 Benin Pregnant women
Forbi et al [56] 2013 West Africa Hübschen et al [89] 2011 Nigeria Cohorts samples
Cohorts study 163 E (154) and A (9) Geretti et al [90] 2010 Ghana HIV+ Crosssectional
E (82) and A (4)
Forbi et al [69] 2010 Nigeria Asymptomatic volunteers
Crosssectional 55 E (53) and A3 (2) Chekaraou et al [32] 2010 Niger Blood donors Crosssectional
E (20), D/E (4)
Candotti et al [91] 2007 Ghana Pregnant women
Crosssectional 70 E (69) and A (1) Vray et al [92] 2006 Senegal Blood donors Crosssectional 32 E (23) and A (9) Huy et al [60] 2006 Ghana Blood donors Crosssectional
12
E (12) Candotti et al [66] 2006 Ghana Blood donors Crosssectional 100 E (87), A (10) and D (3) Fujiwara et al [65] 2005 Benin Blood donors Crosssectional 21 E (20) and A (1) Mulders et al [64] 2004 West Africa November 27, 2018|Volume 10|Issue 11| their study populations. In addition to the presence of other genotypes, including HBV genotypes A and D, studies have rep orted a strong predominance of genotype E [6466] . Simi lar observations have led several authors to support further the common presence of HBV genotype E in West African populations [24] . Indeed, the predominance and almost exclusive circulation of genotype E in sub Saharan Africa certainly indicates its West African origin [6769] . Its distribution is limited to West Africa, unlike other HBV genotypes, despite the migration of slaves from West Africa to North America [66] . This review also reports low genetic diversity of HBV genotype E in West Africa (Figure 2 ) [64, 66] . The low genome di versity and large distribution of genotype E in West Africa suggests a recent introduction of this genotype in the human host [64, 70] . It is possible that it has been introduced relatively recently into an animal reservoir (the chimpanzee) as well as for HIV or that variant of genotype D (the closest to genotype E) has acquired an evolutionary advantage [66] . HBV genotypes A and D were also reported in this review with respective prevalence of 7.8% (126/1620, 95%CI: 0.0650.092) and 0.74% (12/1620, 95%CI: 0.0040.013). HBV ge notype A, which is also found in subSaharan Africa, has been reported in eight of the 10 countries included in this review. Indeed, genotype E is predominant in West Africa, while genotype A has a relatively high prevalence in East Africa [71] . In 2006, Candotti et al [66] reported a prevalence of 10% and 3%, respectively, for HBV genotypes A and D in blood donors in Ghana. Similar results have also highlighted the cocirculation of genotypes A and D in Ghana, Mali, Côte d'Ivoire and Nigeria [59] . The majority of genotypes A identified in Burkina Faso are quasiA3 genotypes (A3Q) documented in West African populations [72] . Indeed, data from previous studies su ggest a predominance of the A1 genotype in East Africa and the A3 genotype in West and Central Africa, while the A2 subgenotype has a high frequency in North Africa where the genotype D is predominant. Africa has a high diversity of HBV genotypes and subgenotypes displaying distinct geographical distributions. Genotype A is found mainly in southeastern Africa, genotype E in western and central Africa and genotype D prevails in northern Africa. Genotype E is rarely found outside Africa, except in individuals of African descent.
Characterization of HBV genotypes allows clinicians to determine patients' response to treatment and potential risks of complications [58, 73] . Flink et al [74] have indeed reported that genotype A responds better to interferon alpha and pegIFNα than genotype D. Gen otype recombination occurs in areas where multiple genotypes are in cocirculation, thus facilitating di versification between individuals within the general population. Our review reports a recombination pre valence of HBV genotype E with genotypes A and D of 0.87% (14/1599, 95%CI: 0.0050.015). A/B, A/C, A/E, C/E, D/E and D/E/A recombination have been reported in West Africa [58] . Recombination requires co infection with more than one genotype in the same patient. Appropriate treatment and elimination of risky Abubakar et al [93] 2017 Nigeria HCV+ Prospective 173 HCV G1 (159) and G2 (14) Ndiaye et al [94] 2015
Senegal Drug users Cohort study 25 HCV G1 (21), G2 (1), G3 (1) and G4 (2) Henquell et al [95] 2016
Burkina Faso woman Case report 1 HCV G5 (1) Opaleye [82] 2016
Nigeria HBV+ Cross-sectional 14 HDV G1 (14) De Paschale et al [12] 2014
Benin Pregnant women Prospective 6 HCV G1 (1), G2 (5) Honge et al [76] 2014
Guinea Bissau HIV+ Cross-sectional 8 HCV G2 (8) Zeba et al [96] 2014
Burkina Faso Blood donors Cross-sectional 36 HCV G1 (4), G2 (22) , G3 (8), G4 (2) Forbi et al [56] 2013
Nigeria Apparently healthy adult Cross-sectional 12 HAV sub-G1A (12) Diarra et al [97] 2013
Mali Diabetic Prospective 25 HCV G1 (7) and G2 (18) Bouare et al [98] 2013
Mali Old women Prospective 14 HCV G1 (2) and G2 (12) Forbi et al [47] 2012 Nigeria Asymptomatic indigenes Prospective 60 HCV G1 (51) and G2 (9) Sombie et al [99] 2011
Burkina Faso HCV+ Prospective 38 HCV G1 (10), G2 (27) and G5 (1) Bengue et al [100] 2008
Côte d'Ivoire Blood donors Prospective 27 HCV G1 (21), G2 (5) and G5 (1) Plamondon et al [101] 2007
Guinea Bissau Adult volunteers Cross-sectional 57 HCV G1 (1) and G2 (56) Simpore et al [102] 2005
Burkina Faso Pregnant women Prospective 5 HCV G1 (2) and G2 (3) Rouet et al [103] 2004
Côte d'Ivoire HIV+/Pregnant women Cross-sectional 6 HCV G1 (3) and G2 (3) Agwale et al [104] 2004
Nigeria HIV+ under ART Prospective 12 HCV G1 (9) and G2 (3) Candotti et al [45] 2003
Ghana Blood donors Cross-sectional 23 HCV G1 (3) and G2 (20) Buisson et al [105] 2000
Nigeria Acute hepatitis Cross-sectional 7 HEV G3 (7) Saito et al [79] 1999
Ghana HIV+ and HIVCross-sectional 9 HGV G1 (9) Wansbrough-Jones et al [106] 1998
Ghana Blood donors Cross-sectional 7 HCV G1 (2) and G2 (5) Oni et al [107] 1996
Nigeria blood donors Cross-sectional 5 HCV G1 (2) behavior in people infected with the virus are therefore necessary for a considerable reduction in the spread of recombinant viruses.
Genotypes of HCV and other hepatitis viruses
The data in this review report five circulating HCV genotypes in the WAEMU countries, Ghana and Nigeria, with an overall predominance of genotype 1 (56.4%, 298/528). The prevalence of HCV genotype 1 has been reported by several authors in Nigeria, Senegal and Côte d'Ivoire, who record the most data presented in this review. Genotype 2 with a general frequency of 40.0% (211/528) was the main genotype found in Benin, Burkina Faso, Ghana, GuineaBissau and Mali ( Figure 2 ). Indeed, several previous studies have re ported a predominance of HCV genotype 2 in West Africa [75] . Most authors suggest a West African genotype 2 origin of HCV in the region, including The Gambia and GuineaBissau [46] . Indeed, HCV genotyping data in GuineaBissau report an almost exclusive predominance of genotype 2 [76] . Candotti et al [45] reported 87.0% of genotype 2 was associated with chronic HCV infection with 13% of cases for genotype 1. In a study in Ghana in HCV/HIV coinfected patients, HCV sequences were phylogenetically assigned genotype 2 and subtypes 21 and 2r [77] . Although no published data on HCV gen otypes were found in Togo, genotypes 2 and 1 were the most frequently isolated, with respective prevalence 73.2% and 17.1%, in a study conducted in 2014 in the Togolese general population.
Genotype 2 is, therefore, predominant in Togo, as it is in most parts of West Africa (unpublished data). In Martinique, where three quarters of the slaves sent in the 17th and 18th centuries came from West Africa, there is a great diversity of genotype 2 [78] . The majority of molecular and epidemiological studies suggest that HCV genotype 2 has been present in West Africa for several centuries. G h a n a G h a n a E F 6 6 2 0 4 6 G h a n a B F G h a n a G h a n a B F B F B F G h a n a Table 1 . Table 2 .
Data on the genotypes of other hepatitis viruses that are very infrequent or with relatively high frequencies in some areas have also been reported in this review. HAV genotype 1 and HEV and HDV were reported in Nigeria, while genotype 1 of HGV was found in Ghana. HAV, whose transmission is closely associated with lack of clean drinking water, unsuitable food, inadequate sanitation and poor personal hygiene, is prevalent in parts of Nigeria (World Health Organization). HDV is a satellite virus of HBV, because HDV only infects people with HBV. Limited data is available on circulating HDV genotypes. In a study in Togo, it was reported that 94.3% of the general population was infected with genotype 1, and 5.7% was infected with genotype 5. Studies on HGV are very limited [57, 79] . The analysis of the 5% untranslated region nucleotide sequence of the genome of the HGV shows that the nine Ghanaian isolates of the HGV belong to genotype 1, the WestAfrican type of the HGV [79] .
CONCLUSION
The complexity of hepatitis virus genotypes often leads to a specificity of treatment associated with the genotype. The present review reporting a mapping of genotypes of hepatitis viruses A, B, C, D, E and G in the WAEMU, Ghana and Nigeria, reveals that the majority of studies conducted in Ghana and Nigeria have very little information on hepatitis D and G. In the WAEMU area including Ghana and Nigeria, HBV strains were classified as genotypes E, A, D with a predominance of genotype E and serotype ayw4. Genotype E is characterized by a high prevalence, low genetic diversity and wide geographical distribution.
The majority of HCV genotype data came from Nigeria, Senegal and Côte d'Ivoire were characteri zed by a predominance of genotype 1, while a high prevalence of genotype 2 was found in Benin, Burkina Faso, Ghana, in GuineaBissau and Mali. Further studies on the clinical implications of HBV genotype E are needed for the development of an effective treatment for HBV in West Africa. Monitoring the dis tribution of the different genotypes is also needed to reduce recombination levels and prevent the em ergence of other viral strains. There is a diversity of genotypes and subtypes of hepatitis viruses with risks of recombination and emergence of even more virulent forms. Hepatitis viruses do not need a passport or visa to move from one country to another, and they have preceded us in WAEMU or ECOWAS. It is therefore appropriate for us to develop the adequate means to prevent, treat and even eradicate these viral infections using a vaccine covering all variants.
